Pharmaceutically active secondary metabolites of microorganisms

Applied Microbiology and Biotechnology

Volumn 52, Issue 4, 1999, Pages 455-463

  Demain, A L ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPICILLIN; ANTHELMINTIC AGENT; ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; ANTIMIGRAINE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; AZITHROMYCIN; BIALAPHOS; CEFACLOR; CEFALEXIN; CEFIXIME; CEFOTAXIME; CEFOXITIN; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; CYCLOSPORIN A; ENZYME INHIBITOR; FLOMOXEF; IMMUNOSUPPRESSIVE AGENT; MYCOTOXIN; PACLITAXEL; PENICILLIN G; SULTAMICILLIN; UNINDEXED DRUG;

ANTIBIOTIC BIOSYNTHESIS; BACTERIAL METABOLISM; BACTERIUM CULTURE; BIOTECHNOLOGY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SYNTHESIS; FUNGUS CULTURE; IMMUNOMODULATION; NONHUMAN; SHORT SURVEY; STREPTOMYCES;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTICHOLESTEREMIC AGENTS; ANTIFUNGAL AGENTS; ANTIPARASITIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOTOXINS;

ACTINOBACTERIA (CLASS); BACTERIA (MICROORGANISMS); FUNGI; STREPTOMYCES;

EID: 0032745552     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002530051546     Document Type: Short Survey

References (68)

1. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J (1980) Mevinolin. A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77:3957-3961
2. Barriere JC, Berthaud N, Beyer D, Dutka-Malen S, Paris JM, Desnottes JF (1998) Recent developments in streptogramin research. Curr Pharm Design 4: 155-180
3. Bentley R (1997) Microbial secondary metabolites play important roles in medicine; prospects for discovery of new drugs. Perspect Biol Med 40: 364-394
4. Berdy J (1995) Are actinomycetes exhausted as a source of secondary metabolites? Proceedings of the 9th International Symposium on The Biology of Actinomycetes Part 1. Allerton Press, New York, pp 3-23
5. Birnbaum J, Kahan FM, Kropp H, MacDonald JS (1985) Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Amer J Med 78 Suppl.6A: 3-21
6. Birnbaum J, Stapley EO, Miller AK, Wallick H, Hendlin D, Woodruff HB (1978) Cefoxitin, a semisynthetic cephamycin: a microbiological overview. J Antimicrob Chemother 4 (Suppl) B: 15-32
7. Black MT, Bruton G (1998) Inhibitors of bacterial signal peptidases. Curr Pharmaceut Design 4: 133-154
8. Borel JF, Feurer C, Gabler HU, Stähelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6: 468-475
9. Breiman RF, Butler JC, Tenover FC, Elliot JA, Facklam RR (1994) Emergence of drug-resistant pneumococcal infections in the United States. JAMA 271: 1831-1835
10. Brown AG (1986) Clavulanic acid, a novel β-lactamase inhibitor - a case study in drug discovery and development. Drug Design Deliv 1: 1-21
11. Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH (1976) Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc Perkin Trans I: 1165-1170
12. Bush K (1997) Antimicrobial agents. Curr Opin Chem Biol 1: 169-175
13. Clark AM (1996) Natural products as a resource for new drugs. Pharmaceut Res 13: 1133-1141
14. Connolly JD, Hill RA (1991) Dictionary of terpenoids. Chapman and Hall, London
15. Cragg GM, Newman DJ, Snader KM (1997) Natural products in drug discovery and development. J Nat Prod 60: 52-60
16. Debono M (1994) The echinocandins: antifungals targeted to the fungal cell wall. Expert Opin Invest Drugs 3: 821-829
17. Dekker KA, Inagaki T, Nomura E, Gootz T, Huang LH, Kohlbrenner WE, Matsunaga Y, McGuirk PR, Sakakibara T, Sakemi S, Suzuki Y, Yamauchi Y, Kojima Y, Kojima N (1997) Novel anti-Helicobacter pylori antibacterials. Abstract P22, 5th International Conference on Biotechnology of Microbial Products: Novel Pharmacological and Agrobiological Activities. Williamsburg, Va, p 26
18. Demain AL (1983) New applications of microbial products. Science 219: 709-714
19. DiMasi JA, Seibring MA, Lasagna L (1994) New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther 55: 609-622
20. Dumont FJ, Su Q (1996) Mechanism of action of the immunosuppressant rapamycin. Life Sci 58: 373-395
21. Endo A, Kuroda M, Tsujita Y (1976) ML-236B and ML-236 C, new inhibitors of cholesterogenesis produced by Penicillium citrinin. J Antibiot 29: 1346-1348
22. Endo A (1979) Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot 32: 852-854
23. Fenical W, Jensen PR (1993) In: Attaway DH, Zaborsky OR (eds) Marine biotechnology I: pharmaceutical and bioactive natural products. Plenum, New York
24. Goldman DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, Schlosser J, Martone WJ (1996) Strategies to prevent and control the emergence and spread of antimicrobial- resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 275: 234-240
25. Hawksworth DL (1991) The fungal dimension of biodiversity: magnitude, significance, conservation. Mycol Res 95: 641-655
26. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM, Foltz EL, Woodruff HB, Mata JM, Hernandez S, Mochales S (1969) Phosphonomycin. A new antibiotic produced by strains of Streptomyces. Science 166: 122-123
27. Hidy PH, Baldwin RS, Greasham RL, Keith CL, McMullen JR (1977) Zearelenone and some derivatives: production and biological activities. Adv Appl Microbiol 22: 59-82
28. Hutchinson CR (1997) Antibiotics from genetically engineered microorganisms. In: Strohl WR (ed) Biotechnology of antibiotics, 2nd edn. Marcel Dekker, New York, pp 683-702
29. Jefferys EG (1970) The gibberellin fermentation. Adv Appl Microbiol 13: 283-316
30. Kahan FS, Kahan FM, Goegelman RT, Currie SA, Jackson M, Stapley EO, Miller TW, Miller AK, Hendlin D, Mochales S, Hernandez S, Woodruff HB, Birnbaum J (1979) Thienamycin, a new β-lactam antibiotic. I. Discovery, taxonomy, isolation, and physical properties. J Antibiot 32: 1-12
31. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka M (1987) FK-506, a novel immunosuppressant isolated from Streptomyces. 1. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot 40: 1249-1255
32. Lee WA, Gu L, Kikszal AR, Chu N, Leung K, Nelson PH (1990) Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharmaceut Res 7: 161-166.
33. Lewis K (1994) Multidrug resistance pumps in bacteria: variations on a theme. Trends Biochem Sci 19: 119-123
34. Liu J (1993) FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. Trends Pharmacol Sci 14: 182-188
35. McAlpine J (1998) Unnatural natural products by genetic manipulation. In: Sapienza DM, Savage LM (eds) Natural products II: New technologies to increase efficiency and speed. International Business Communications, Southborough, Mass, pp 251-278
36. McArthur HAI (1997) The novel avermectin, Doramectin - a successful application of mutasynthesis. Abstract S13, 5th International Conference on Biotechnology of Microbial Products: Novel Pharmacological and Agrobiological Activities. Williamsburg, Va, p. 20
37. Mishima H, Ide J, Muramatsu S, Ono M (1983) Milbemycins, a new family of macrolide antibiotics. Structure determination of milbemycins D, E, F, G, H, J and K. J Antibiot 36: 980-990
38. Moellering RC (1997) The specter of glycopeptide resistance: current trends and future considerations. 37th Intersci conf antimicrob agents chemother, Toronto
39. Nichterlein T, Kretschmar M, Hof H (1996) RP 59500, a streptogramin derivative, is effective in murine listerosis. J Chemother 8: 107-112
40. Nikaido H (1996) Multidrug efflux pumps of gram-negative bacteria. J Bacteriol 178: 5853-5819
41. Oki T, Yoshimoto A (1979) Antitumor antibiotics. In: Perlman D (ed) Annual reports on fermentation processes, vol 3. Academic Press, New York, pp 215-251
42. Peng Y, Demain AL (1998) A new hydroxylase system in Actinomadura sp cells converting compactin to pravastatin. J Industr Microbiol Biotechnol 20: 373-375
43. Roessner CA, Scott AI (1996) Genetically engineered synthesis of natural products: from alkaloids to corrins. Annu Rev Microbiol 50: 467-490
44. Schwartz RE, Sesin DF, Joshua H, Wilson KE, Kempf AJ, Goklen KA, Kuehner D, Gailliot P, Gleason C, White R, Inamine E, Bills G, Salmon P, Zitano L (1992) Pneumocandins from Zalerion arboricola I. Discovery and isolation. J Antibiot 45: 1853-1866
45. Serizawa N, Matsuoka T (1991) A two component-type cytochrome P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Biochim Biophys Acta 1084: 35-40
46. R) revisited: another point of view. Experientia 52: 5-13
47. Stapley EO (1982) Avermectins, antiparasitic lactones produced by Streptomyces avermitilis isolated from a soil in Japan. In: Umezawa H, Demain AL, Hata R, Hutchinson CR (eds) Trends in antibiotic research. Japan Antibiotic Research Association, Tokyo, pp 154-170
48. Stapley EO, Jackson M, Hernandez S, Zimmerman SB, Currie SA, Mochales S, Mata JM, Woodruff HB, Hendlin D (1972) Cephamycins, a new family of β-lactam antibiotics. I. Production by actinomycetes, including Streptomyces lactamdurans sp. n. Antimicrob Agents Chemother 2: 122-131
49. Stead P (1997) Natural products drug discovery - new technologies and approaches. Drug Discov Today 2: 256-259
50. Stephens C, Shapiro L (1997) Bacterial protein secretion - a target for new antibiotics? Chem Biol 4: 637-641
51. Stierle A, Strobel G, Stierle D (1993) Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science 260: 214-216
52. Stinson SC (1996) Drug firms restock antibacterial arsenal. Chem Eng News 74 (39): 75-100
53. Strohl WR (1997) Industrial antibiotics: today and the future. In: Strohl WR (ed) Biotechnology of antibiotics, 2nd edn. Marcel Dekker, New York, pp 1-47
54. Sum P-E, Sum F-W, Projan SJ (1998) Recent developments in tetracycline antibiotics. Curr Pharm Drugs 4: 119-132
55. Tally FA, Wendler PA, Houman F (1997) Translation targets for antifungal drug development. Abstract S5, 5th International Conference on Biotechnology of Microbial Products: Novel Pharmacological and Agrobiological Activities. Williamsburg, Va, p 19
56. Tanaka H, Omura S (1997) Screening of novel receptor-active compounds of microbial origin. In: Kleinkauf H, von Döhren H (eds) Biotechnology, vol 7. Products of secondary metabolism. VCH, Weinheim, pp 107-132
57. Tenover FC, Hughes JM (1996) The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens. JAMA 275: 300-304
58. Tomasz M (1995) Mitomycin C: small, fast and deadly (but very selective). Curr Biol 2: 575-579
59. Truscheit E, Frommer W, Junge B, Müller L, Schmidt DD, Wingender W (1981) Chemistry and biochemistry of microbial α-glucosidase inhibitors. Angew Chem Int Ed Engl 20: 744-761
60. Umezawa H (1972) Enzyme inhibitors of microbial origin. University Park Press, Baltimore.
61. Umezawa H (1982) Low-molecular-weight inhibitors of microbial origin. Annu Rev Microbiol 36: 75-99
62. Vaara M (1993) Antibiotic-supersusceptible mutants of Escherichia coli and Salmonella typhimurium. Antimicrob Agents Chemother 37: 2255-2260
63. Verdine GL (1996) The combinatorial chemistry of nature. Nature 384 (Suppl): 11-13
64. Vezina D, Kudelski A, Sehgal SN (1975) Rapamycin (AY 22,989), a new antifungal antibiotic. 1. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 28: 721-726
65. Vining LC, Taber WA (1979) Ergot alkaloids. In: Rose AH (ed) Economic microbiology, vol 3: Secondary products of metabolism. Academic Press, London, pp 389-420
66. Wall ME, Wani MC (1995) Campothecin and taxol: discovery to clinic. Cancer Res 55: 753-760
67. White TC (1997) Antifungal drug resistance in Candida albicans. ASM News 63: 427-433
68. Winkelmann G (1986) Iron complex products (siderophores). In: Pape H, Rehm H-J (eds) Biotechnology, vol 4. Microbial products 2. VCH, Weinheim, pp 215-243